Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

ACC.14: Darapladib may not affect development of coronary plaque

Darapladib did not significantly reduce the risk of cardiovascular death, MI or stroke associated with coronary heart disease, according to study results presented March 30 at the American College of Cardiology (ACC) scientific session in Washington, D.C.

ACC.14: For procedural success, balloon-expandable valve may be better CHOICE

Using a balloon-expandable valve instead of a self-expandable valve may be a better option among patients undergoing transcatheter aortic valve replacement (TAVR), based on research presented March 30 at the American College of Cardiology (ACC) annual scientific session in Washington, D.C. Researchers found more device success with the balloon-expandable device and similar rates of mortality and complications.

ACC.14: Cardiovascular disease guidelines may not be best risk estimators

Differences between cardiovascular disease prevention guidelines mean that different proportions of individuals would be eligible for statin therapy, according to results presented March 29 at the American College of Cardiology (ACC) scientific session in Washington, D.C. 

Thumbnail

ACC.14: CoreValve meets superiority mark in high-risk patients

WASHINGTON, D.C.—The FDA skipped convening an expert panel after release of positive results for the CoreValve Extreme Risk cohort and later approved the device. Will it do the same for CoreValve as a treatment for patients who are considered at high surgical risk, based on findings presented March 29 at the American College of Cardiology scientific session in Washington, D.C.?

Prominent cardiac cell biologist Jennifer Van Eyk, PhD, joins Cedars-Sinai to direct new advanced clinical biosystems research institute

Prominent proteomic and cardiac scientist Jennifer Van Eyk, PhD, has been named the inaugural director of Cedars-Sinai's Advanced Clinical Biosystems Research Institute.

Thumbnail

Talking statins

I heard on my car radio that 12.8 million more Americans would receive statins under new cholesterol guidelines. Well, they got the number right.

Guidelines swell ranks for statins by almost 13 million

Almost 13 million Americans between 40 and 75 years old would become eligible for statin therapy under new cholesterol guidelines, according to a study published online March 19 in the New England Journal of Medicine.

ACC.14: Will TAVR be the talk of the town?

Looking for an ice-breaker at the upcoming American College of Cardiology (ACC) scientific session? Try bringing up transcatheter aortic valve replacement (TAVR).

Displaying 1273 - 1280 of 2350

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.